We are live on
!
Find out more
DMKJ
David M. Knott Jr Portfolio holdings
AUM
$168M
1-Year Est. Return
60.36%
This Fund
S&P 500
This Quarter
Est. Return
-2.49%
1 Year Est. Return
+60.36%
3 Year Est. Return
+143.93%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$168M
AUM Growth
-$47.9M
(-22%)
Cap. Flow
-$34.3M
Cap. Flow
% of AUM
-20.4%
Top 10 Holdings %
Top 10 Hldgs %
60.49%
Holding
95
New
8
Increased
17
Reduced
13
Closed
10
Top Buys
| 1 |
Iovance Biotherapeutics
IOVA
|
+$5.12M |
| 2 |
Agios Pharmaceuticals
AGIO
|
+$2.13M |
| 3 |
Relmada Therapeutics
RLMD
|
+$2.08M |
| 4 |
Ardelyx
ARDX
|
+$1.37M |
| 5 |
TG Therapeutics
TGTX
|
+$1.34M |
Top Sells
| 1 |
Calumet Specialty Products
CLMT
|
+$44M |
| 2 |
Catalyst Pharmaceutical
CPRX
|
+$1.64M |
| 3 |
TECX
Tectonic Therapeutic
TECX
|
+$1.54M |
| 4 |
Travere Therapeutics
TVTX
|
+$1.36M |
| 5 |
Biohaven
BHVN
|
+$1.25M |
Sector Composition
| 1 | Healthcare | 53.57% |
| 2 | Financials | 19.49% |
| 3 | Communication Services | 15.66% |
| 4 | Technology | 1.31% |
| 5 | Energy | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
AtriCure
ATRC
$1.83B
| $1.47M | 0.87% |
51,400
| – | – |
|
|
27
Ardelyx
ARDX
$1.28B
| $1.24M | 0.74% |
+207,000
| New | +$1.37M |
|
28
Panagram BBB-B CLO ETF
CLOZ
$764M
| $1.23M | 0.73% |
47,807
| – | – |
|
29
Johnson & Johnson
JNJ
$607B
| $1.2M | 0.72% |
4,922
-2,000
| -29% | -$466K |
|
30
Rezolute
RZLT
$438M
| $1.13M | 0.67% |
370,000
+30,000
| +9% | +$90K |
|
31
Orchestra BioMed
OBIO
$221M
| $1.08M | 0.64% |
253,651
+3,651
| +1% | +$15.5K |
|
32
Madrigal Pharmaceuticals
MDGL
$12.5B
| $1.05M | 0.62% |
2,000
| – | – |
|
33
Vera Therapeutics
VERA
$2.95B
| $1.05M | 0.62% |
26,000
| – | – |
|
|
CNTB
34
Connect Biopharma Holdings
CNTB
$148M
| $1.02M | 0.6% |
387,835
+187,835
| +94% | +$490K |
|
35
iShares Biotechnology ETF
IBB
$9.26B
| $929K | 0.55% |
5,500
| – | – |
|
36
Pfizer
PFE
$144B
| $908K | 0.54% |
32,337
| – | – |
|
37
Bristol-Myers Squibb
BMY
$122B
| $826K | 0.49% |
13,622
-8,378
| -38% | -$488K |
|
38
Canadian Natural Resources
CNQ
$89.3B
| $819K | 0.49% |
16,800
| – | – |
|
39
Biogen
BIIB
$30.1B
| $733K | 0.44% |
4,000
-2,000
| -33% | -$369K |
|
40
Ultragenyx Pharmaceutical
RARE
$3.01B
| $693K | 0.41% |
33,069
+13,063
| +65% | +$294K |
|
41
Apple
AAPL
$4.85T
| $633K | 0.38% |
2,494
| – | – |
|
42
Microsoft
MSFT
$2.95T
| $592K | 0.35% |
1,600
| – | – |
|
43
Verastem
VSTM
$487M
| $551K | 0.33% |
+104,000
| New | +$641K |
|
44
ADMA Biologics
ADMA
$2.03B
| $542K | 0.32% |
60,200
| – | – |
|
45
IBM
IBM
$197B
| $519K | 0.31% |
2,142
| – | – |
|
|
PTHS
46
Pelthos Therapeutics
PTHS
$95.6M
| $443K | 0.26% |
21,073
+1,792
| +9% | +$42.5K |
|
47
Kura Oncology
KURA
$973M
| $429K | 0.26% |
52,767
+13,558
| +35% | +$116K |
|
48
Evolus
EOLS
$385M
| $408K | 0.24% |
99,338
| – | – |
|
49
Cullinan Oncology
CGEM
$1.05B
| $344K | 0.2% |
+24,200
| New | +$311K |
|
50
Solid Biosciences
SLDB
$899M
| $339K | 0.2% |
47,143
-115,297
| -71% | -$741K |
|
Similar funds
DI
WA
MC
WFS
TT
7CM
MAG
PFA